Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or...
Reexamination Certificate
2007-05-16
2010-12-14
Saunders, David A (Department: 1644)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
C435S018000, C435S029000
Reexamination Certificate
active
07851143
ABSTRACT:
Provided are in vitro and in vivo methods for determining whether a patient with Fabry disease will respond to treatment with a specific pharmacological chaperone.
REFERENCES:
patent: 5900360 (1999-05-01), Welch et al.
patent: 6270954 (2001-08-01), Welch et al.
patent: 6274597 (2001-08-01), Fan et al.
patent: 6541195 (2003-04-01), Welch et al.
patent: 6583158 (2003-06-01), Fan et al.
patent: 6589964 (2003-07-01), Fan et al.
patent: 6599919 (2003-07-01), Fan et al.
patent: 6774135 (2004-08-01), Fan et al.
patent: 6916829 (2005-07-01), Fan et al.
patent: 7141582 (2006-11-01), Fan et al.
patent: WO 2004/103368 (2004-12-01), None
Fan, et al., 1999, “Accelerated Transport and Maturation of Lysosomal Alpha-Galactosidase in Fabry Lymphoblasts by an Enzyme Inhibitor,” Nat Med., vol. 5, No. 1: p. 112-115.
Desnick et al., in Scriver, et al. (eds.), 2001, Metabolic and Molecular Bases of Inherited Disease, 8th ed. Graw-Hill, New York: p. 3733-3774.
Fan, et al., 2003, “A contradictory treatment for lysosomal storage disorders: inhibitors enhance mutant enzyme activity,” Trends in Pharm. Sci., vol. 24, No. 7: p. 355-360.
Bishop, et al., 1985, “Molecular Genetics,”Am. J. Hum. Genet., vol. 37: p. A144.
Bishop et al., 1986, “Human Alpha-Galactosidase A: Nucleotide Sequence of a cDNA Clone Encoding the Mature Enzyme,”Proc. Natl. Acad. Sci. USA, vol. 83: p. 4859-4863.
Brady, et al., 1967, “Enzymatic Defect in Fabry's Disease. Ceramidetrihexosidase Deficiency,”N. Engl. J Med., vol. 276: p. 1163-1167.
Branum, et al., 1988, “Effect of Two Anticoagulants on Leukocyte Yield and Function, and on Lysosomal Enzyme Activity,”Clin Chem, vol. 34, No. 1: p. 110-113.
Brown, et al., 1997, “Strategies for Correcting the Delta F508 CFTR Protein-Folding Defect,”Journal of Bioenergetics and Biomembranes, vol. 29, No. 5: p. 491-502.
Calhoun, et al., 1985, “Fabry Disease: Isolation of a cDNA Clone Encoding Human Alpha-Galactosidase A,”Proc. Natl. Acad. Sci. USA, vol. 82: p. 7364-7368.
Davies, et al., 1996, “Fabry Disease: Fourteen Alpha-Galactosidase A Mutations in Unrelated Families From the United Kingdom and Other European Countries,”Eur. J. Hum. Genet., vol. 4: p. 219-224.
Eng, et al., 1993, “Nature and Frequency of Mutations in the Alpha-Galactosidase A Gene That Cause Fabry Disease,”Am. J. Hum. Genet., vol. 53: p. 1186-1197.
Eng, et al., 1997, “Fabry Disease: Thirty-Five Mutations in the Alpha-Galactosidase A Gene in Patients with Classic and Variant Phenotypes,”Mol. Med., vol. 3: p. 174-182.
Fuller, et al., 2005, “Urinary Lipid Profiling for the Identification of Fabry Hemizygotes and Heterozygotes,”Clinical Chemistry, vol. 51: p. 688-694.
Ishii, et al., 1996, “Aggregation of the Inactive Form of Human α-Galactosidase in the Endoplasmic Reticulum,”Biochem. Biophys. Res. Comm., vol. 220: p. 813-815.
Kornreich et al., 1989, “Nucleotide Sequence of the Human Alpha-Galactosidase A Gene,”Nucleic Acids Res., vol. 17: p. 3301-3302.
Kusiak, et al., 1978, “Purification and Properties of the Two Major Isozymes of Alpha-Galactosidase from Human Placenta,”J. Biol. Chem., vol. 253, No. 1: p. 184-190.
Mayes, et al., 1981, “Differential Assay for Lysosomal Alpha-Galactosidases in Human Tissues and its Application to Fabry's Disease,”Clin. Chim. Acta., vol. 112, No. 2: p. 247-251.
Nakao, et al., 1995, “An Atypical Variant of Fabry's Disease in Men with Left Ventricular Hypertrophy,”N. Engl. J. Med., vol. 333: p. 288-293.
Park, et al., 2003, “Long-Term Correction of Globotriaosylceramide Storage in Fabry Mice by Recombinant Adeno-Associated Virus-Mediated Gene Transfer,”Proc. Natl. Acad. Sci. USA, vol. 100: p. 3450-3454.
Shin, S., 2007, “Screening for Pharmacological Chaperonses in Fabry Disease,”Materials and Methods, vol. 359: p. 168-173.
Tsuji et al., 1987, “Signal Sequence and DNA-Mediated Expression of Human Lysosomal Alpha-Galactosidase A,”Eur. J Biochem., vol. 165: p. 275-280.
Weinberg, et al., 1998, “Effect of Shipment, Storage, Anticoagulant, and Cell Separation on Lymphocyte Proliferation Assays for Human Immunodeficiency Virus-Infected Patients,”Clin Diagn Lab Immunol, vol. 5, No. 6: p. 804-807.
Welch, et al., 1996, “Influence of Molecular and Chemical Chaperones on Protein Folding,”Cell Stress and Chaperones, vol. 1, No. 2: p. 109-115.
Frustaci, Andrea, et al., “Improvement in Cardiac Function in the Cardiac Variant of Fabry's Disease with Galactose-Infusion Therapy”, New England Journal of Medicine, vol. 345, No. 1, pp. 25-32 (Jul. 5, 2001).
Sawkar, Anu R., et al., “Gaucher Disease-Associated Glucocerebrosidases Show Mutation-Dependent Chemical Chaperoning Profiles”, Chemistry & Biology, vol. 12, pp. 1235-1244 (Nov. 2005).
Shin, Sang H., et al., “Prediction of Response of Mutated α-Galactosidase A to a Pharmacological Chaperone”, Pharmacogenet Genomics, vol. 18, No. 9, pp. 773-780 (Sep. 2008).
Yam, Gary Hin-Fai, et al., “Pharmacological chaperone corrects lysosomal storage in Fabry disease caused by trafficking-incompetent variants”, AM. J. Physiol. Cell Physiol., vol. 290, pp. C1076-C1082 (Apr. 2006).
Supplementary European Search Report for European Application No. 07 797 506.8 dated Feb. 15, 2010.
Castelli Jeff
Kaneski Christine
Lockhart David
Ludwig Karin
Murray Gary
Amicus Therapeutics, Inc.
Hoffman & Baron LLP
Saunders David A
LandOfFree
Assays for diagnosing and evaluating treatment options for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Assays for diagnosing and evaluating treatment options for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Assays for diagnosing and evaluating treatment options for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4151254